BioSpace News Archive

BioVie Inc. (NASDAQ: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, today announced the results of a Type B meeting request submitted to the Food & Drug Administration (“FDA”) regarding its planned Phase 3 study of BIV201 (continuous infusion terlipressin) in hepatorenal syndrome–acute kidney injury (“HRS-AKI”).

Adela (formerly DNAMx) has launched with $60 million USD in Series A financing to enable the detection of cancer and other high-morbidity, high-mortality conditions through a blood test that harnesses the potential of the methylome

Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored development of ThermoDox®, the Company’s proprietary heat-activated liposomal encapsulation of doxorubicin.

Cocrystal Pharma, Inc. announces the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1.

aTyr Pharma, Inc. today announced that the company will host a virtual Key Opinion Leader (KOL) event on the current treatment options for pulmonary sarcoidosis on Tuesday, June 29th at 5:00pm ET/2:00pm PT.

Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, announced that Greg Sukay has joined the company as Vice President, Manufacturing and Process Technologies.

Veralox Therapeutics today announced the appointment of Michael S. Hanna , MD, FACC, as chief medical officer.

Lipocine Inc. today announced that clinical data will be presented at The International Liver Congress™ 2021, the annual meeting of the European Association for the Study of the Liver (“EASL”), Digital Event, on June 23-26 , 2021.

GT Biopharma, Inc.announced Jeffrey S. Miller, M.D., Deputy Director of the Masonic Cancer Center and Consulting Chief Scientific Officer, provided an update concerning GTB-3550 TriKE.

Nasus Pharma Ltd announced positive results from a pilot trial of intranasal powder-based Epinephrine.